Information Provided By: 
Fly News Breaks for April 19, 2016
NVTA, MYGN
Apr 19, 2016 | 11:36 EDT
William Blair analyst Amanda Murphy believes Invitae's (NVTA) hereditary breast cancer test reimbursement from Noridian does not have relevance for Myriad Genetics (MYGN). She points out that Myriad's MyRisk assay is a pan cancer hereditary cancer panel, making Invitae's CPT code 81342 not an appropriate code for Myriad to bill. The analyst has an Outperform rating on Myriad shares. The stock is down 8% to $35.82 after Invitae announced this morning its reimbursement price.
News For MYGN;NVTA From the Last 2 Days
There are no results for your query MYGN;NVTA
